{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:30:43Z","timestamp":1794022243018,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejps.2021.105788","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T05:46:17Z","timestamp":1615095977000},"page":"105788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice"],"prefix":"10.1016","volume":"161","author":[{"given":"Yihai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105788_bib0001","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: role of STAT3, Mitochondria, and Redox Aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.ejps.2021.105788_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24213903","article-title":"1,25-Dihydroxyvitamin D Decreases Tertiary Butyl-Hydrogen Peroxide-Induced Oxidative Stress and Increases AMPK\/SIRT1 Activation in C2C12 Muscle Cells","volume":"24","author":"Chang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2021.105788_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","article-title":"Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction","volume":"19","author":"Connelly","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ejps.2021.105788_bib0004","doi-asserted-by":"crossref","first-page":"E629","DOI":"10.1152\/ajpendo.00171.2003","article-title":"Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise","volume":"285","author":"Coven","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ejps.2021.105788_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","article-title":"Metabolism of the failing heart and the impact of SGLT2 inhibitors","volume":"15","author":"Garcia-Ropero","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejps.2021.105788_bib0006","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbrc.2020.04.002","article-title":"Fibroblast growth factor 19 alleviates palmitic acid-induced mitochondrial dysfunction and oxidative stress via the AMPK\/PGC-1alpha pathway in skeletal muscle","volume":"526","author":"Guo","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejps.2021.105788_bib0007","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.118.031373","article-title":"Reappraisal of Ischemic Heart Disease","volume":"138","author":"Kaski","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejps.2021.105788_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2021.105788_bib0009","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","article-title":"No direct effect of SGLT2 activity on glucagon secretion","volume":"62","author":"Kuhre","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejps.2021.105788_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108889","article-title":"Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling","volume":"315","author":"Lee","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejps.2021.105788_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110642","article-title":"Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway","volume":"501","author":"Lu","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ejps.2021.105788_bib0012","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","author":"Maayah","year":"2020","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejps.2021.105788_bib0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function","volume":"6","author":"Maejima","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejps.2021.105788_bib0014","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41598-018-20276-6","article-title":"Pre-revascularization coronary wedge pressure as marker of adverse long-term left ventricular remodelling in patients with acute ST-segment elevation myocardial infarction","volume":"8","author":"Marc","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejps.2021.105788_bib0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejps.2021.105788_bib0016","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejps.2021.105788_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1751-7133.2008.07210.x","article-title":"Arterial stiffness and vascular load in heart failure","volume":"14","author":"Ooi","year":"2008","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ejps.2021.105788_bib0018","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ejps.2021.105788_bib0019","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCRESAHA.117.309633","article-title":"AMP-Activated Protein Kinase: an Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System","volume":"120","author":"Salt","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.ejps.2021.105788_bib0020","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejps.2021.105788_bib0021","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"374","author":"Sarafidis","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejps.2021.105788_bib0022","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejps.2021.105788_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2019.12.004","article-title":"Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial","volume":"221","author":"Tripolt","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejps.2021.105788_bib0024","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejps.2021.105788_bib0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2021.105788_bib0026","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin Attenuates Na(+)\/H(+) Exchanger-1 in Cardiofibroblasts via AMPK Activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejps.2021.105788_bib0027","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejps.2021.105788_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"10.1016\/j.ejps.2021.105788_bib0029","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:59:46Z","timestamp":1760529586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"alternative-id":["S0928098721000907"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105788","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105788"}}